CliffBio
biologic

Creon

pancrelipase

Loss of exclusivityMarch 2025projected — 12-year biologic exclusivity estimate
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameCreon
Active ingredientpancrelipase
Strength36,000USP UNITS; 114,000USP UNITS; 180,000USP UNITS
Dosage formCapsule, Delayed Release
RouteOral
ModalityBiologic
FDA approvalMarch 2013
Marketing statusRx

More from AbbVie Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Creon patent cliff — loss of exclusivity March 2025 | CliffBio